海西新药：林慧怡获委任为联席公司秘书

Core Viewpoint - Hai Xi New Drug (02637) announced the resignation of Ms. Chen Xiaolin from multiple positions effective November 21, 2025, and the appointment of Ms. Lin Huiyi to these roles starting the same date [1] Group 1 - Ms. Chen Xiaolin has resigned as the co-secretary of the company [1] - Ms. Chen Xiaolin has also resigned as the authorized representative under the Hong Kong Listing Rules and the Companies Ordinance [1] - Ms. Lin Huiyi has been appointed as the co-secretary and authorized representative effective November 21, 2025 [1]